IPO - Arcus Biosciences, Inc.

Form Type: 8-K

Filing Date: 2025-02-19

Corporate Action: Ipo

Type: New

Accession Number: 000119312525029591

Filing Summary: On February 18, 2025, Arcus Biosciences, Inc. entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC to offer and sell 13,636,364 shares of its common stock at an offering price of $11.00 per share. The closing of this offering occurred on February 19, 2025, and the company anticipates net proceeds of approximately $141.6 million for use in ongoing research and development, manufacturing costs, and general corporate purposes. The agreement includes standard representations, warranties, conditions to closing, and indemnification obligations. Additionally, an opinion regarding the shares' validity was provided by Latham & Watkins LLP, with a detailed Underwriting Agreement and legal opinions filed as exhibits in the report.

Document Link: View Document